scholarly journals Growth and body composition in children with chronic kidney disease

2007 ◽  
Vol 97 (2) ◽  
pp. 232-238 ◽  
Author(s):  
R. Rashid ◽  
E. Neill ◽  
H. Maxwell ◽  
S. F. Ahmed
Keyword(s):  
Chronic Kidney Disease ◽  
Body Composition ◽  
Kidney Disease ◽  
Growth Failure ◽  
Potential Effect ◽  
Complex Problem ◽  
Physiological Mechanisms ◽  
Growth And Nutrition

Growth failure is a common yet complex problem of childhood chronic kidney disease caused by multiple factors encountered due to the primary disease or secondary to the renal impairment. This review seeks to describe the various patho-physiological mechanisms contributing to growth failure in the various stages of childhood with particular emphasis on nutritional problems and endocrine dysfunction encountered whilst managing these children. In addition, we shall examine the role of body composition in chronic kidney disease, their relationship with growth and nutrition and the potential effect of abnormalities in fat mass and lean mass on long-term morbidity and mortality.

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

scholarly journals Intensity of hydration changes the role of renin–angiotensin–aldosterone system blockers in contrast-induced nephropathy risk after coronary catheterisation in patients with chronic kidney disease

2017 ◽  
Vol 18 (2) ◽  
pp. 147032031770889 ◽  
Author(s):  
Xiao-sheng Guo ◽  
Deng-xuan Wu ◽  
Wei-jie Bei ◽  
Hua-long Li ◽  
Kun Wang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Body Weight ◽  
Kidney Disease ◽  
Angiotensin Receptor Blockers ◽  
Group Versus ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Potential Effect ◽  
Contrast Induced Nephropathy ◽  
Converting Enzyme Inhibitors

Objective: This study evaluated the potential effect of hydration intensity on the role of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) on contrast-induced nephropathy in patients with renal insufficiency. Methods: All eligible patients were included and stratified according to hydration intensity defined as saline hydration volume to body weight tertiles: <10.21 mL/kg, 10.21 to <17.86 mL/kg, and ⩾17.86 mL/kg. Results: In total, 84 (6.7%) of 1254 patients developed contrast-induced nephropathy: 6.2% in the ACEI/ARB group versus 10.8% in the non-ACEI/ARB group ( P=0.029), with an adjusted odds ratio (OR) of 0.89 (95% confidence interval (CI) 0.46–1.73, P=0.735). The incidence of contrast-induced nephropathy was lower in the ACEI/ARB group than in the non-ACEI/ARB group in the second tertile ( P=0.031), while not significantly different in the first ( P=0.701) and third ( P=0.254) tertiles. ACEIs/ARBs were independently associated with a lower contrast-induced nephropathy risk (OR 0.26, 95% CI 0.09–0.74, P=0.012) and long-term all-cause death (hazard ratio 0.461, 95% CI 0.282–0.755, P=0.002) only in the second hydration volume to body weight tertile. Conclusion: The effects of ACEIs/ARBs on contrast-induced nephropathy risk vary according to saline hydration intensity in chronic kidney disease patients, and may further reduce contrast-induced nephropathy risk in patients administered moderate saline hydration.

Treatment of growth failure with growth hormone in children with chronic kidney disease: an open-label long-term study

2010 ◽  
Vol 74 (08) ◽  
pp. 97-105 ◽  
Author(s):  
D. Müller-Wiefel ◽  
H. Frisch ◽  
T. Tulassay ◽  
L. Bell ◽  
Z. Zadik
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Hormone ◽  
Kidney Disease ◽  
Growth Failure ◽  
Open Label ◽  
Term Study ◽  
Long Term Study

scholarly journals Mechanisms by Which Dehydration May Lead to Chronic Kidney Disease

2015 ◽  
Vol 66 (Suppl. 3) ◽  
pp. 10-13 ◽  
Author(s):  
C. Roncal-Jimenez ◽  
M.A. Lanaspa ◽  
T. Jensen ◽  
L.G. Sanchez-Lozada ◽  
R.J. Johnson
Keyword(s):  
Chronic Kidney Disease ◽  
Risk Factor ◽  
Kidney Disease ◽  
Central America ◽  
Kidney Diseases ◽  
Long Term Effects ◽  
Acute Renal Dysfunction ◽  
Chronic Kidney Diseases

Dehydration, a condition that characterizes excessive loss of body water, is well known to be associated with acute renal dysfunction; however, it has largely been considered reversible and to be associated with no long-term effects on the kidney. Recently, an epidemic of chronic kidney disease has emerged in Central America in which the major risk factor seems to be recurrent heat-associated dehydration. This has led to studies investigating whether recurrent dehydration may lead to permanent kidney damage. Three major potential mechanisms have been identified, including the effects of vasopressin on the kidney, the activation of the aldose reductase-fructokinase pathway, and the effects of chronic hyperuricemia. The discovery of these pathways has also led to the recognition that mild dehydration may be a risk factor in progression of all types of chronic kidney diseases. Furthermore, there is some evidence that increasing hydration, particularly with water, may actually prevent CKD. Thus, a whole new area of investigation is developing that focuses on the role of water and osmolarity and their influence on kidney function and health.

scholarly journals Role of Pulse Wave Velocity in Patients with Chronic Kidney Disease Stages 3-5 on Long-Term Follow-Up

Pulse ◽  
2014 ◽  
Vol 2 (1-4) ◽  
pp. 1-10 ◽  
Author(s):  
Hiromichi Suzuki ◽  
Tsutomu Inoue ◽  
Mami Dogi ◽  
Tomohiro Kikuta ◽  
Tsuneo Takenaka ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pulse Wave Velocity ◽  
Wave Velocity ◽  
Pulse Wave ◽  
Long Term Follow Up ◽  
Disease Stages

scholarly journals Chronic Kidney diseases: Role of Vitamin-K and Vitamin-D

2021 ◽  
Vol 4 (03) ◽  
Author(s):  
Vinod Kumar Varapete ◽  
Ravindra B N ◽  
Jerin S Shaji ◽  
Yaseen Mulla ◽  
Jiss P Jose ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
High Blood Pressure ◽  
Vitamin K ◽  
Kidney Diseases ◽  
Elevated Serum

Chronic kidney disease is the most common form of kidney disease and high blood pressure is the most common cause the pressure on the glomeruli increases due to high blood pressure which can prove to be very dangerous. Lack in VITAMIN D isn't restricted to the dynamic chemical, calcitriol (25-hydroxycholecalciferol) is likewise insufficient in many patients with constant kidney sickness (CKD), free of their fundamental renal capacity. Diminishes in calcitriol happen generally right off the bat in the movement of kidney illness and may originate before the increment in PTH. These progressions in calcitriol and PTH add to the upkeep of moderately ordinary serum and calcium fixations until the glomerular filtration rate (GFR) diminishes to <20–25%; nonetheless, the outcome is the potential advancement of bone and vascular sickness. Vitamin K intake and long-term vitamin K status are expressed by a high percentage of undercarboxylated OC (uOC). Vitamin D, which is needed for uOC development, and parathyroid hormone (PTH), which is often elevated in patients with CKD, are also affected by osteocalcin levels. Therefore, elevated serum uOC is present in patients with chronic kidney disease (CKD) with hyperparathyroidism, but this does not generally mean that they are deficient in vitamin K.

EFFECTIVENESS OF ANTIAGGREGANT THERAPY ON KIDNEY ACTIVITY IN THE PREDIALYSIS STAGE OF CHRONIC KIDNEY DISEASE

2020 ◽  
Vol 6 (1) ◽  
pp. 55-60
Author(s):  
Khabib Barnoev ◽  
◽  
Sherali Toshpulatov ◽  
Nozima Babajanova ◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Comparative Study ◽  
Functional Status ◽  
Stage Ii ◽  
Term Administration ◽  
Antiaggregant Therapy

The article presents the results of a study to evaluate the effectiveness of antiaggregant therapy on the functional status of the kidneys in 115 patients with stage II and III chronic kidney disease on the basis of a comparative study of dipyridamole and allthrombosepin. Studies have shown that long-term administration of allthrombosepin to patients has led to improved renal function.

ASSESSMENT OF KIDNEY FUNCTIONAL RESERVE ON THE BACKGROUND OF ANTI-AGGREGATE THERAPY IN CHRONIC KIDNEY DISEASE II-III STAGE

2020 ◽  
Vol 6 (1) ◽  
pp. 49-54
Author(s):  
Khabib Barnoev ◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Comparative Study ◽  
Early Stage ◽  
Raw Material ◽  
Functional Reserve ◽  
Functional Reserves ◽  
Term Administration ◽  
Antiaggregant Therapy

The article presents the results of a study to assess the functional reserve of the kidneys against the background of a comparative study of antiaggregant therapy dipyridamole and allthrombosepin in 50 patients with a relatively early stage of chronic kidney disease. Studies have shown that long-term administration of allthrombosepin to patients has resulted in better maintenance of kidney functional reserves. Therefore, our research has once again confirmed that diphtheridamol, which is widely used as an antiaggregant drug in chronic kidney disease, does not lag behind the domestic raw material allthrombosepin

Sign in / Sign up

Export Citation Format

Share Document